Aldeyra Therapeutics (ALDX) Stock Price
$6.95 0.5%
to add to portfolio
AI Score
-
Alternative
3 -
Fundamental
1 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Aldeyra Therapeutics, AI stock picks, stock alerts and much more.
ALDX AI Stock Analysis
AI stock analysis for ALDX is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Aldeyra Therapeutics (ALDX) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Aldeyra Therapeutics (ALDX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Aldeyra Therapeutics (ALDX), currently trading at $6.95, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ALDX
-
Aldeyra Therapeutics, Inc.
-
Symbol
ALDX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
414.7M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21 0.9% |
4 |
 |
Inovio Pharmaceuticals INO |
$2.02 1.7% |
2 |
 |
Moderna MRNA |
$35.35 1% |
3 |
 |
Anavex Life Sciences AVXL |
$8.9 0.1% |
5 |
 |
BridgeBio Pharma BBIO |
$32.31 0.9% |
4 |
News
ALDX Alternative Data
Web Traffic
Aldeyra Therapeutics receives an estimated 2168 monthly visitors to aldeyra.com, which is down by -71.3% over the last month.
-
Web Traffic
2168
-
Change from Previous Month
71.3%
-
3 Month Change
77.4%
-
YoY Change
77.4%
News Mentions
Aldeyra Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Reddit Mentions
Aldeyra Therapeutics has been mentioned an estimated 1 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
Twitter Followers
Aldeyra Therapeutics has 438 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
438
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
1.1%
-
YoY Change
1.1%
Facebook Engagement
Aldeyra Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Followers
3,793 are following Aldeyra Therapeutics on LinkedIn, up by 0.6% over the last month.
-
LinkedIn Followers
3793
-
Daily Change
0.1%
-
1 Month Change
0.6%
-
3 Month Change
1.7%
Job Postings
Aldeyra Therapeutics currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Aldeyra Therapeutics has 14 employees, down by -6.7% over the last month.
-
LinkedIn Employees
14
-
Daily Change
0%
-
1 Month Change
6.7%
-
3 Month Change
17.6%
-
YoY Change
17.6%
Business Outlook
According to employee reviews, the business outlook among employees at Aldeyra Therapeutics is 100 out of 100 (very bullish).
-
Business Outlook
100
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
ALDX Financials
ALDX Key Metrics
-
Total Revenue
$0
-
Net Income
-$15.1M
-
Earnings per Share
-$0.25
-
Free cash flow
-$8M
-
EBITDA
-$16.1M
-
EBITDA Ratio
0
-
Total Assets
$117.3M
ALDX 2-year Revenue & Income
ALDX 2-year Free Cash Flow
ALDX Technicals
ALDX SMA
ALDX RSI
FAQ
What's the current price of Aldeyra Therapeutics (ALDX) Stock?
The price of an Aldeyra Therapeutics (ALDX) share is $6.95.
What's the market cap of Aldeyra Therapeutics?
The current market cap of Aldeyra Therapeutics is 414.7M.
Should I buy or sell ALDX?
Aldeyra Therapeutics exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Aldeyra Therapeutics a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Aldeyra Therapeutics stock. There are several bearish signals and market challenges that could negatively impact Aldeyra Therapeutics' future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Aldeyra Therapeutics (ALDX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Aldeyra Therapeutics stock right now, as the outlook appears bearish.
What are some stocks similar to Aldeyra Therapeutics (ALDX) that investors often compare it to?
Aldeyra Therapeutics (ALDX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Aldeyra Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Aldeyra Therapeutics' stock price to be around $6.37 in 2026. Starting from the current price of $6.95, this represents a 8.3% change in price, indicating a bearish outlook for the stock.
How to buy Aldeyra Therapeutics (ALDX) Stock?
Aldeyra Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Aldeyra Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.